THE DEFINITIVE GUIDE TO HBOT VITAERIS 320

The authors of An additional paper noted the administration of HBOT as adjuvant therapy for acute macular neuroretinopathy in systemic lupus erythematosus in conjunction with immunosuppression in two patients [eleven].Despite the fact that CRAO is the only real vascular illness from the retina exactly where HBOT is usually recommended via the UHMS,